ClinicalTrials.gg
WithdrawnNCT01234298NSSUpdated Jun 3, 2021

SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia

A Phase 3 interventional study of SPD489 Low-Dose and SPD489 High-Dose in Negative Symptoms of Schizophrenia, sponsored by Shire. Withdrawn. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study was discontinued due to non-safety related business prioritization decisions

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.

Enrollment
11th of 11
0 · median 20
Started
2012
with 1 other
Phase 3
4 of 11
none open now
Registered
2nd of 11
by date

Among the 11 studies in Schizophrenia by Takeda, this one is the 11th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 3, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Schizophrenia by Takeda as a file.
02

Study summary

To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.

03

Conditions studied

  • Negative Symptoms of Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has diagnosis of schizophrenia for at least 2 years
  • Subject has persistent predominant negative symptoms
  • Subject has 2 or more persistent predominant negative symptoms (affective flattening, alogia, avolition apathy, and anhedonia-asociality) determined to have been present for at least 6 months
  • Subject is maintained on antipsychotic monotherapy or polytherapy with no more than 2 antipsychotic medications
  • Subject has been clinically stable and is in the non-acute phase of illness

Exclusion criteria

Exclusion Criteria:

  • Subject has clinically notable positive symptoms
  • Subject is considered to be treatment
  • Subject has current history of substance abuse/dependance
  • Subject is considered a suicide risk or risk to harm others
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    SPD489 Low-Dose

    Drug: SPD489 Low-Dose

  • Experimental
    SPD489 High-Dose

    Drug: SPD489 High-Dose

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks

    Also known as: Vyvanse, Lisdexamfetamine dimesylate, LDX

  • SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks

    Also known as: Vyvanse, Lisdexamfetamine dimesylate, LDX

  • DrugPlacebo

    Placebo capsule taken once-daily for up to 26 weeks

06

What researchers measure

Primary outcomes

  1. Negative Symptom Assessment (NSA-16) total score

    Time frame: up to 26 weeks

Secondary outcomes

  1. Positive and Negative Syndrome Scale (PANSS)

    Time frame: up to 26 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2012; primary completion for Feb 2014, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2010
First posted
Nov 4, 2010
StartEst.
Jan 27, 2012
Primary completionEst.
Feb 24, 2014
CompletionEst.
Feb 24, 2014
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01234298
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 4, 2010
Start date
Jan 27, 2012 (estimated)
Primary completion
Feb 24, 2014 (estimated)
Completion
Feb 24, 2014 (estimated)
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion